Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Controlled Substances Scheduling topic
No spam. Unsubscribe anytime.
Committee introduces controlled-substances scheduling updates including synthetic opioids and hormones
Summary
RS 31,822, presented by Nikki Chopsky of the Division of Occupational and Professional Licenses, would add multiple illicit synthetic substances to Schedule I, add synthetic anabolic steroids to Schedule III, and place zuranolone (Zirzuve) on Schedule IV; the committee voted to introduce the RS.
Nikki Chopsky, Health Professions Bureau Chief at the Division of Occupational and Professional Licenses and executive officer for the boards of Medicine, Nursing and Pharmacy, told the House Health and Welfare Committee that RS 31,822 updates the Idaho Controlled Substances Act.
Chopsky said the bill, consistent with Idaho Code 37-2702A and the state's Uniform Controlled Substances Act, would add 24 illicit substances—including benzodiazepine derivatives, synthetic fentanyls, synthetic cannabinoids and synthetic cathinones ("bath salts")—to Schedule I. The draft would also add 23 man-made testosterone derivatives to Schedule III and would add zuranolone (referred to in the presentation as "Zirzuve"), an FDA-approved treatment for postpartum depression, to Schedule IV. She said the Idaho Board of Pharmacy discussed the proposed language in public meetings beginning in September 2024 and that no public feedback had been received to date.
"At this time, we are not aware of any concerns with the proposed language. There is no expected fiscal impact to the general fund," Chopsky said. She asked the committee to print RS 31,822 for a bill hearing. Representative Healy moved to introduce the RS; the committee approved the introduction by voice vote and the chair announced the motion carried.
